SCHEMBL622653

SCHEMBL622653

O=Cc1ccc(-c2ccccc2)o1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.66
ALDH1A1 P00352 7/20 0.66
LMNA P02545 5/20 0.66
TDP1 Q9NUW8 2/20 0.65
CYP2E1 P05181 1/20 0.62
CYP3A4 P08684 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2B6 P20813 1/20 0.62
CYP2C19 P33261 1/20 0.62
POLB P06746 3/20 0.62
L3MBTL1 Q9Y468 1/20 0.62
SMN1; SMN2 Q16637 5/20 0.58
HPGD P15428 4/20 0.58
GFER P55789 1/20 0.58
MAPT P10636 6/20 0.56
MEN1 O00255 4/20 0.54
KMT2A Q03164 4/20 0.54
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Furan SCHEMBL28377570 0.91 KDM4E (0.56) KDM4EALDH1A1LMNATDP1CYP2E1
SCHEMBL396870 0.89 ALDH1A1 (0.80) KDM4EALDH1A1LMNATDP1CYP2E1
SCHEMBL28307056 0.87 ALDH1A1 (0.66) KDM4EALDH1A1LMNATDP1CYP2E1
SCHEMBL8243143 0.87 ALDH1A1 (0.67) KDM4EALDH1A1LMNATDP1CYP2E1
SCHEMBL3023730 0.85 KDM4E (0.59) KDM4EALDH1A1LMNATDP1CYP2E1
SCHEMBL3038241 0.84 KDM4E (0.57) KDM4EALDH1A1LMNATDP1CYP2E1
SCHEMBL13043078 0.84 KDM4E (0.57) KDM4EALDH1A1LMNATDP1CYP2E1
SCHEMBL6656195 0.81 ALDH1A1 (0.61) KDM4EALDH1A1LMNATDP1CYP2E1
SCHEMBL12177745 0.81 ALDH1A1 (0.69) KDM4EALDH1A1LMNATDP1CYP2E1
SCHEMBL8806045 0.80 ALDH1A1 (0.57) KDM4EALDH1A1LMNATDP1CYP2E1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101223130-A Glutamate aggrecanase inhibitors WYETH CORP (US) 2008-07-16 CN claimed
EP-1599476-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES NEUROSEARCH A/S (DK) 2005-11-30 EP claimed
WO-2004076453-A1 NOVEL DIAZABICYCLIC ARYL DERIVATIVES NEUROSEARCH A/S (DK) 2004-09-10 WO claimed
US-20260136833-A1 OPTOELECTRONIC COMPONENT WITH A PHOTOACTIVE LAYER DESIGNED AS A PLANAR HETEROJUNCTION HELIATEK GMBH (DE) 2026-05-14 US disclosed
EP-4548730-A1 OPTOELECTRONIC COMPONENT WITH A PHOTOACTIVE LAYER DESIGNED AS A PLANAR HETEROJUNCTION Heliatek GmbH (DE) 2025-05-07 EP disclosed
CN-119452771-A Optoelectronic component with photoactive layer designed as a planar heterojunction 赫里亚泰克有限责任公司 2025-02-14 CN disclosed
US-20250011292-A1 NOVEL RHODANINE DERIVATIVES AND USES THEREOF GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2025-01-09 US disclosed
CN-118755729-A Screening and application of aptamer specifically binding to heparin binding protein 杭州艾普佳臻生物科技有限公司 2024-10-11 CN disclosed
CN-112469723-B Cationically curable compositions with latent reducing agents exhibiting low cure temperatures 汉高股份有限及两合公司 2024-09-20 CN disclosed
EP-4415704-A1 NOVEL RHODANINE DERIVATIVES AND USES THEREOF Georgia State University Research Foundation, Inc. (US) 2024-08-21 EP disclosed
EP-3860994-B1 TRANSCRIPTION FACTOR BRN2 INHIBITORY COMPOUNDS AS THERAPEUTICS AND METHODS FOR THEIR USE UNIV BRITISH COLUMBIA (CA) 2024-08-14 EP disclosed
US-4944790-A PLANT SAFENING AGENTS FOR USE WITH CERTAIN HERBICIDES CIBA-GEIGY CORPORATION (US) 1990-07-31 US disclosed
EP-0320628-A1 Substituted furan compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase ABBOTT LABORATORIES (US) 1989-06-21 EP disclosed
WO-1989004299-A1 FURAN AND PYRROLE CONTAINING LIPOXYGENASE INHIBITING COMPOUNDS ABBOTT LABORATORIES (US) 1989-05-18 WO disclosed
EP-0268554-A2 1,5-Diphenyl pyrazole-3-carbonic-acid derivatives for the protection of cultured plants CIBA-GEIGY AG (CH) 1988-05-25 EP disclosed
US-4439608-A 2-[2-(5-Phenylfurfurylamino)ethyl]pyridines NORWICH EATON PHARMACEUTICALS, INC. (US) 1984-03-27 US disclosed
US-4264325-A INCLUDING POLYACRYLONITRILE, POLYESTERS, CELLULOSE ACETATES, AND POLYAMIDES CIBA-GEIGY CORPORATION (US) 1981-04-28 US disclosed
US-4189589-A OPTICAL BRIGHTENERS FOR TEXTILES CIBA-GEIGY CORPORATION (US) 1980-02-19 US disclosed
US-3962284-A 3-(5-ARYL-2-FURYL)-3-HYDROXYPROPIONIC ACIDS AND ETHYL ESTERS MORTON-NORWICH PRODUCTS, INC. (US) 1976-06-08 US disclosed
US-3946049-A 5-PHENYL-2-FURAMIDOXIMES MORTON-NORWICH PRODUCTS, INC. (US) 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260136833-A1 OPTOELECTRONIC COMPONENT WITH A PHOTOACTIVE LAYER DESIGNED AS A PLANAR HETEROJUNCTION HCN2, HCN3, HCN4 KDM4E 4242/4885ALDH1A1 2078/4885LMNA 1498/4885
US-20250011292-A1 NOVEL RHODANINE DERIVATIVES AND USES THEREOF ACE2, RARG, ALAD KDM4E 4281/4885ALDH1A1 955/4885LMNA 4733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.